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Abstract
Background: Thiamazole is a widely used antithyroid agent that has been approved for the treatment of
hyperthyroidism. Although thiamazole-induced hepatotoxicity is a main side effect, it may progress to liver failure
in a very few cases.
Case Presentation: We described a 24-year-old patient with hyperthyroidism and trilogy of Fallot, who developed
liver failure due to thiamazole. Liver biopsy showed intrahepatic cholestasis, mild inflammatory infiltrates, as well as
significant fibrosis, indicating both acute and chronic liver injuries. Although a series of potent therapies were
given, the patient deceased due to severe liver decompensation.
Conclusions: This case suggests that thiamazole-induced hepatotoxicity in the setting of advanced fibrosis
increases the risk of poor outcome. Regular liver function monitoring during thiamazole therapy is therefore
important.
Background
Liver dysfunction is a common complication observed in
hyperthyroidism, either as a result of hyperthyroidism
and/or the use of antithyroid drugs (ADs). ADs includ-
ing thiamazole (MMI) and propylthiouracil (PTU) are
widely used for treating hyperthyroidism. Despite their
relatively safe profiles, both can induce hepatotoxicity
presenting as hepatocellular or cholestatic injury [1-6];
however, liver failure has rarely been encountered.
Because thyroidectomy and radioiodine are contraindi-
cated in the setting of liver failure, few treatment
options are available.
Trilogy of Fallot (TOF) including pulmonic stenosis,
interatrial septal defect, and right ventricular hypertro-
phy is a congenital cardiac disease. Due to the impair-
ment of pulmonary outflow, right-sided congestive heart
failure can be observed at its advanced stage, leading to
the occurrence of passive liver congestion or develop-
ment of hepatic fibrosis [7].
Here, we report the first case of a patient with
hyperthyroidism and TOF that was recently referred to
our hospital for acute-on-chronic liver failure (ACLF)
related to MMI.
Case Presentation
A 24-year-old man was admitted to our hospital due to
diarrhea, progressive jaundice, light stool, fatigue and
excessive sweating for 18 days. He was diagnosed with
TOF at age 3, and had undergone pulmonary valvotomy
and closure of the foramen ovale at age 19. The former
procedure failed, while the latter was successful. Since
then hyperthyroidism was confirmed, and MMI (20 mg
per day) was intermittently taken for 1 year because he
refused to receive radioiodine therapy. Neither thyroid
nor liver function had been regularly monitored during
the treatment period or in the following 4 years. MMI
(20 mg per day) was continuously taken by himself for 20
days prior to the onset of the symptoms, which, however,
did not arouse his alertness, and MMI administration
was continued until his admission. He denied use of any
other concomitant prescriptions (including non-ADs),
over-the-counter drugs or herbal remedies. The patient
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allergies or liver disease.
Physical examination revealed a 112 heart beats per
minute with evidences of tremor, generalized icterus,
and pigmentation of the skin on the bilateral tibia.
Marked carotid pulsation, jugular distension, and an
enlarged thyroid gland with vascular murmur were
observed. Thrill on palpation and mid-systolic murmur
on auscultation were evident in the pulmonary area. A
strong collapsing pulse and pistol shot sound was noted
in the peripheral arteries. The liver edge and the spleen
edge descended 1.5 cm and 3 cm below the costal mar-
gin, respectively, and peripheral edema was also noticed.
Laboratory tests revealed the following biochemical
results (with the normal range in brackets): ALT 75 U/L
(5 to 40), ALP 133 U/L (15 to 130), ALT/ALP ratio
0.56, TBIL 587.9 μmol/L (3.0 to 20.0), DBIL 288.2
μmol/L (2.0 to 6.0), FT4 154.8 pmol/L (7.90 to 14.10),
FT3 30.8 pmol/L (3.86 to 6.00), thyroid-stimulating hor-
mone less than 0.01 μIU/ml (0.340 to 5.600), PT 22.2
seconds (9.0 to 12.8), and international normalized ratio
2.3 (0.8 to 1.4). Viral serologies (hepatitis A, B, C, and E
viruses; human immunodeficiency virus; Epstein-Barr
virus and cytomegalovirus) and autoimmunity markers
(antinuclear antibody, antimitochondrial antibody, anti-
neutrophil cytoplasmic antibody, anti-smooth-muscle
antibody, and anti-liver-kidney microsome antibody)
were all negative. Screening studies were performed to
detect genetic and metabolic liver diseases, which
excluded hematochromatosis, Wilson’s disease, and
alpha 1-antitrypsin deficiency. The color Doppler echo-
cardiography showed evidence of severe pulmonary ste-
nosis, right ventricular hypertrophy, tricuspid
incompetence with systolic regurgitation, and enlarged
right atrium (Figure 1). Moreover, ultrasonography of
the abdomen revealed signs of hepatic parenchymal
injury, inferior vena cava dilation and splenomegaly.
Drug induced lymphocyte stimulation test for MMI
was performed, and the procedure was briefly described
as follows: Lymphocytes isolated from the heparinized
peripheral blood sample of patient were incubated with
serial concentrations of the purified MMI (M8506,
Sigma). After that, the proliferative response was
assessed by measuring incorporated
3H-thymidine
uptake. The patient showed a positive result, with the
Stimulation Index of 2.19.
MMI was discontinued on admission. The patient was
treated with PTU (50 mg 8 hourly) and propranolol
(40 mg 3 times daily). Methylprednisolone (40 mg daily)
and liver protecting preparation (e.g. diammonium glycyr-
rhizinate, ursodeoxycholic acid, and ademetionine) were
also administrated. The patient underwent three sessions
of plasma exchange, and an 8-hour continuous hemofiltra-
tion. His general condition, liver functions and other
biochemical parameters gradually improved with ALT,
ALP, TBIL and PT values, while FT3 and FT4 approxi-
mately restored to normal levels; however, two days later,
his liver function worsened again (Figure 2). A liver biopsy
was performed on day 18 after admission. Pathological
findings showed that the portal tracts were expanded by
moderate inflammatory infiltration composed of lympho-
cytes, neutrophils and eosinophils. The portal tracts were
surrounded by proliferative cholangioles, and some with
bile plugs. Nodular regeneration of the hepatic parench-
yma was delimited by loosened fibrous septa. Diffused
swelling and enlargement of hepatocytes were detected
within hepatic lobules, particularly around central veins.
Feathery degeneration was also observed in some hepato-
cytes, indicative of intracellular cholestasis, but necrosis
was absent within portal areas and lobules (Figure 3).
Figure 1 The color Doppler echocardiographic findings. A: M-mode and two-dimensional echocardiography shows the right atrial
dimensions are 5.71×5.85 cm. B: Continuous wave Doppler shows the tricuspid valve regurgitation velocity is 4.6 m/s and the pressure gradient
between right ventricle and right atrium is 85 mmHg.
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gressively deteriorated, and grade II encephalopathy devel-
oped. The patient subsequently experienced hypoxemia,
hypotension, decreased urinary outflow, and metabolic
acidosis. Although mechanical ventilation and intensive
therapies were applied, unfortunately, the progression of
his medical conditions could not be suspended, and he
eventually expired as a result of multiple organ failure on
day 27 after admission.
Conclusions
This patient presented with acute-on-chronic liver fail-
ure. After extensive investigations, viral hepatitis, auto-
immune liver diseases, Wilson’s disease,
hemochromatosis, and alpha 1-antitrypsin deficiency
were excluded. There was no history of alcohol abuse or
exposure to toxic substances. We sought for etiologies
of liver injury based on clinical course and suggestive
changes in liver histology.
Figure 2 Serial levels of biochemical parameters during hospitalization. ALT: alanine aminotransferase; ALP: alkaline phosphatase; TBIL: total
bilirubin; PT: prothrombin time; FT3: free triiodothyronine; FT4: free thyroxine; MMI: thiamazole; PTU: propylthiouracil; PE: plasma exchange; CHF:
continuous hemofiltration; LST: lymphocyte stimulation test; MV: mechanical ventilation.
Figure 3 Histological findings of the liver specimen. A: Liver biopsy showing intracanalicular bile plugs (black arrow) and enlarged
hepatocytes with feathery degeneration, indicative of intrahepatic cholestasis. Moderate inflammatory infiltration, composed of lymphocytes,
neutrophils, as well as eosinophils (inset), was presented in portal area (Hematoxylin and Eosin staining, ×400). B: Expanded portal tracts
accompanied by significant hepatic fibrosis (Masson Tri-chrome staining, ×100).
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intrahepatic cholestasis with mild inflammatory infil-
trates indicative of acute liver injury. MMI-induced
hepatotoxicity was highly suspected, based on: (1) a
1-year history of intermittent use of MMI, which was
continuously taken for 20 days before the symptoms
onset; (2) the absence of other concomitantly admini-
strated prescriptions, over-the-counter drugs and herbs;
(3) the onset of hepatotoxicity was temporally related to
the start of MMI therapy before admission; (4) the
patient’s condition was relatively stable prior to MMI
therapy; (5) lymphocyte stimulation test for MMI was
positive; and (6) the common causes of liver injury were
ruled out. We also assessed the patient using the
CIOMS/RUCAM scale, and on the basis of his score 7,
he was judged “probable” [8].
Although MMI is generally safe in treating hyperthyr-
oidism, hepatotoxicity has been described as a major
side effect with approximately 30 cases described in the
English literature [4]. However, there is, up till now,
only one case reporting MMI-related acute liver failure
in a patient with hyperthyroidism and chronic hepatitis
B [9]. Symptom-onset of this adverse effect ranges from
3 days to 5 months following the initiation of MMI
therapy [4]. The MMI-induced liver injury usually
appears to be a cholestatic process that is not as severe
or life-threatening as the hepatocellular damage induced
by PTU. Only 6.6% of patients receiving MMI therapy
(30 mg per day) showed elevated ALT and AST levels
twice the upper of the normal range, compared with
26.9% on PTU (300 mg per day) [10]. The typical fea-
tures are elevated serum levels of bilirubin, and histolo-
gical changes of intrahepatic cholestasis with mild
periportal inflammation [1,5,6]. Our patient presented
with a dramatically high level of bilirubin and the ALT/
ALP ratio <2, suggesting the pattern of cholestatic liver
injury. Liver biopsy demonstrated obvious intrahepatic
cholestasis, proliferative cholangioles with bile plugs,
and moderate portal inflammation with eosinophils infil-
tration, which were consistent with characteristic fea-
tures of MMI-induced hepatotoxicity in most reported
cases.
The mechanism underlying MMI-related liver injury
remains unclear, and some researchers proposed that it
is most likely an idiosyncratic (hypersensitive) reaction,
which is often infrequent and unpredictable [4,6,9]. The
onset of symptoms is usually delayed after the start of
drug exposure [5,11]. However, it appears more rapidly
and severely upon rechallenge of the culprit drug [5,11].
Thus, this may reasonably account for severe hepato-
toxicity developed when MMI continuously taken and
the phenomenon of lymphocyte proliferation in vitro.
The liver histology also indicated advanced hepatic
fibrosis and nodular patterns, the hallmark of chronic
liver injury, which reflects, in part, continuous acute
liver injury extended over time. Due to the absence of
other risk factors for causing persistent liver injury, we
suspected that the hepatic fibrosis was mostly associated
with prolonged hepatocytes hypoxia caused by TOF and
hyperthyroidism.
Although central vein/sinusoidal dilation has not been
observed on his liver histology, our patient exhibited
clinical manifestations (e.g. jugular distension, hepato-
megaly, and splenomegaly) and ultrasonographic images
(e.g. enlarged right atrium, inferior vena cava, and hepa-
tic vein dilation) that strongly supported right-sided
heart failure and passive liver congestion resulting from
TOF. Prolonged congestive heart failure can lead to
liver damage, mainly because of decreased hepatic blood
flow, increased venous pressure, and decreased arterial
oxygen saturation [7]. Long-term existence of passive
liver congestion, hepatic fibrosis or even cirrhosis may
be developed [7].
Hyperthyroidism should, in fact, also reasonably account
for chronic liver injury due to quite a long period of non-
controlled hyperthyroidism. Thyroid dysfunction has been
suggested to perturb liver function, and liver disease, in
turn, modulates thyroid hormone metabolism [12]. It is
estimated that about 60.5% of patients with hyperthyroid-
ism exhibited at least one hepatic abnormality upon diag-
nosis [13]. The mechanism is most likely due to
hepatocytes hypoxia, a condition caused by a high demand
for oxygen, but with no appropriate increase in hepatic
blood flow [12]. Previously reported patients with
untreated hyperthyroidism can develop a spectrum of
pathological changes ranging from focal necrosis to cirrho-
sis [14]. In addition, hyperthyroidism further promotes the
progress of liver injury especially in the setting of conges-
tive heart failure [2].
Indeed, the pre-existing chronic liver disease remained
unknown in this patient until the current acute episode,
mainly because of patient’s asymptomatic state, as well
as the paucity of liver function tests due to his poorly
medical compliance. However, it is possible that the pre-
sence of the underlying chronic liver disease secondary
to above medical conditions may have predisposed the
patient to MMI-induced hepatotoxicity.
Appropriate management of both hyperthyroidism and
liver injury is critical for our patient’s condition. Both
thyroidectomy and radioiodine are contraindicated in
patients with liver failure, limiting the options for the
treatment of hyperthyroidism. Switching to PTU has
been reported to be effective in 3 cases of MMI-induced
hepatotoxicity, because the mechanisms responsible for
MMI- and PTU-induced hepatotoxicity differ [5]. PTU,
but not MMI, can block the extrathyroidal conversion
of thyroxine to triiodothyronine, which may lead to a
more rapid reduction in serum triiodothyronine level
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symptoms[1,15]. However, alternative ADs was proposed
to be a risky approach due to the possibility of cross-
reactivity (in up to 50% cases) between two agents [1].
As noted from others, plasma exchange has been used
successfully to treat severe hyperthyroidism. The under-
lying mechanism may be the effective removal of thyroid
hormones, which are almost entirely (>99%) bound to
plasma proteins [16]. Successful use of steroids has been
reported in cases of ADs-related hepatotoxicity; how-
ever, whether it benefits accelerating recovery needs
further assessment.
Our patient’s condition was temporally alleviated
under above combination treatment, but promptly wor-
sened again over the following days. We suspect that
the deterioration of his liver function might be related
to insufficient residual hepatic capacity for regeneration.
In addition, the possibility of cross-reactivity between
MMI and PTU cannot be fully excluded in this patient,
because the progressive elevation of ALT and TBIL
levels was observed shortly after the initiation of PTU
therapy.
In summary, MMI can induce acute hepatotoxicity,
and particularly in the setting of underlying chronic
liver disease, the possibility of poor outcome may
increase. This case also highlights the importance of
regular monitoring of liver function for patients who
receive MMI therapy for hyperthyroidism, especially
during the first 3 months after initiating therapy. Such
closely monitoring will enable early recognition and
treatment when hepatic abnormalities occur, and pre-
vent the progression of liver lesions.
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